The effectiveness of Allicin on survival of sepsis patients in intensive care units

Phase 1

Recruiting

• Conditions: Sepsis.; Sepsis, unspecified organism; A41.9

• Registration Number: IRCT20220508054780N3
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

Age over 18 years
Diagnosis of sepsis due to lung infection
Not pregnant
Not breastfeeding

Exclusion Criteria

Having Allicin allergies
Having a history of hypotension
Having gastrointestinal bleeding
Having hypotension
Taking warfarin
Having immunodeficiency disorders
Inability of patient to take oral medication
Having hepatic failure
Having renal failure
Having a history of neuromuscular disorders

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
SpO2 level. Timepoint: At the beginning of study and 7 days after intervention. Method of measurement: Pulse Oximeter.;Mortality rate. Timepoint: 7 days after intervention. Method of measurement: Based on acute physiology and chronic health evaluation score (APACHE) II score.;Number of days dependent on ventilator. Timepoint: 7 days after intervention. Method of measurement: The number of days the ventilator is used for the patient.

Secondary Outcome Measures

Name	Time	Method
Dependent on vasopressor rate. Timepoint: 7 days after intervention. Method of measurement: The number of times the drug is prescribed to the patient.;Serum level of acute-phase proteins. Timepoint: At the beginning of study and 7 days after intervention. Method of measurement: C-Reactive Protein (CRP) test.;Incidence of respiratory distress. Timepoint: 7 days after intervention. Method of measurement: Based on patient clinical trials.